Welcome, Guest. Please login or register.
October 23, 2020, 04:02:15 am

Login with username, password and session length

 

Members
Stats
  • Total Posts: 295
  • Total Topics: 154
  • Online Today: 17
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 7
Total: 7

Welcome!

Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Treatment Yields Promising Outcomes in High-Risk Neuroblastoma  (Read 1295 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
Combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy yielded promising two-year event-free survival in pediatric patients with newly diagnosed high-risk neuroblastoma, according to results from a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Approximately 650 children are diagnosed with neuroblastoma each year in North America, and the disease predominantly affects children under the age of five years. Because the symptoms can be non-specific, about half of patients are diagnosed after the cancer has spread and progressed to high-risk neuroblastoma, according to Wayne L. Furman, MD, member of the Department of Oncology at St. Jude Children’s Research Hospital.

Patients with high-risk neuroblastoma undergo intense treatment that includes chemotherapy, surgery, stem cell transplant, radiotherapy, a biologic agent, and treatment with a monoclonal anti-GD2 antibody called dinutuximab. “Despite the aggressive treatment these kids receive, more than half have disease recurrence,” said Furman.

Read more...
https://www.cancerhealth.com/article/new-treatment-yields-promising-outcomes-highrisk-neuroblastoma

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.